Overexpression of Aromatase P450 in Leiomyoma Tissue Is Driven Primarily through Promoter I.4 of the Aromatase P450 Gene (CYP19)

Abstract

The CYP19 gene encoding aromatase P450 (estrogen synthetase) is expressed in several extragonadal sites and regulated in a tissue-specific fashion, which is achieved by alternative use of the seven different promoters (and corresponding exons 1) of the CYP19 gene. Previously, we demonstrated that aromatase P450 is overexpressed in leiomyoma tissue and that in situ estrogen synthesized in leiomyoma tissues possibly plays a role in leiomyoma growth. To elucidate the mechanism of overexpression of aromatase P450, we determined the promoter use of aromatase P450 in leiomyomas. 5'-Rapid amplification of cDNA ends analysis revealed that of six leiomyoma nodules tested, four nodules contained I.4-specific transcript of aromatase P450 alone, one nodule contained PII-specific transcript alone, and the remaining nodule contained both I.4- and PII-specific transcripts simultaneously. The levels of aromatase transcripts were then quantified by competitive RT-PCR assay. Among 21 leiomyomas, I.4-specific transcript and PII-specific transcript were predominant in 18 and 2 leiomyomas, respectively, whereas the remaining leiomyoma was negative for aromatase P450 expression. We next compared the aromatase activity of leiomyoma cells stimulated by promoter-specific regulatory factors. A combination of IL-1beta and dexamethasone, known as a potent inducer of promoter I.4-driven transcription, effectively increased aromatase activity. A combination of (Bt)(2)cAMP, 3-isobutyl-1-myethylxanthine, and PGE(2), known as inducers of promoter II-driven transcription, also increased aromatase activity, but the increases found were smaller than that induced by dexamethasone and IL-1beta. The transcriptional ability of the promoter I.4 sequence was confirmed by transient transfection assay using primary cells released from leiomyomas and established cells from normal myometrium (KW cells). Luciferase vectors containing promoter I.4 sequence (-340/+14 or longer) showed a significant increase in luciferase activity in response to dexamethasone. Deletion or mutation of a putative glucocorticoid-responsive element in the promoter I.4 sequence eliminated promoter activity. These results indicate that promoter I.4 is the major promoter responsible for overexpression of aromatase P450 in leiomyomas and that a glucocorticoid-responsive element within it plays a substantial role in the expression of aromatase P450.

Molecular characterization and expression of cyp19a gene in Carassius auratus

“…Promoters contain specific DNA sequences and response elements that provide an initial binding site for RNA polymerase and for the transcription factors that recruit RNA polymerase. In humans, six promoter regions have been identified in CYP19 genes namely: Ia, Ib, Ic, Id (II), Ie and If; these regions work in the placenta, foetal liver and skin fibroblast, ovary, ovary and testis, placenta and brain, respectively (Mahendroo et al , ; Shozu & Simpson, ; Shozu et al , ). The gonad‐specific promoter is conserved in humans, bovines and avians (Jenkins et al , ; Honda et al , ).…”

Aromatase as a target for treating endometriosis

“…The human aromatase gene was mapped to chromosome 15, band q21 by in situ hybridization studies and was confirmed by recent human genome analysis . The gene consists of nine coding exons.…”

Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas

“…In uterine leiomyoma, aromatase is present at a higher level compared to adjacent normal myometrium and could play a role in leiomyoma growth wreviewed by Shozu et al (61)x. In uterine leiomyoma, aromatase is present at a higher level compared to adjacent normal myometrium and could play a role in leiomyoma growth wreviewed by Shozu et al (61)x.…”